Movatterモバイル変換

[0]ホーム
URL:

IN2014DN03463A - - Google Patents

Download PDF

Info

Publication number
IN2014DN03463A
IN2014DN03463AIN3463DEN2014AIN2014DN03463AIN 2014DN03463 AIN2014DN03463 AIN 2014DN03463AIN 3463DEN2014 AIN3463DEN2014 AIN 3463DEN2014AIN 2014DN03463 AIN2014DN03463 AIN 2014DN03463A
Authority
IN
India
Prior art keywords
relates
tricyclo
sequence
nucleic acid
acid molecule
Prior art date
Application number
Inventor
Christian Leumann
Luis Garcia
Thomas Voit
Original Assignee
Ass Inst De Myologie
Universität Bern
Univ Pierre Et Marie Curie Paris 6
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ass Inst De Myologie, Universität Bern, Univ Pierre Et Marie Curie Paris 6, Inst Nat Sante Rech Med, Centre Nat Rech ScientfiledCriticalAss Inst De Myologie
Publication of IN2014DN03463ApublicationCriticalpatent/IN2014DN03463A/en

Links

Classifications

Landscapes

Abstract

The present invention relates to a nucleic acid molecule containing a sequence of tricyclo nucleosides joined by internucleoside phosphorothioate linkage. The invention also relates to synthetic antisense oligonucleotides and to methods employing the same.
IN3463DEN20142011-10-132014-04-30IN2014DN03463A (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US201161546942P2011-10-132011-10-13
EP11185129.1AEP2581448B1 (en)2011-10-132011-10-13Tricyclo-phosphorothioate DNA
CA2776651ACA2776651C (en)2011-10-132012-04-27Tricyclo-phosphorothioate dna
PCT/EP2012/070349WO2013053928A1 (en)2011-10-132012-10-12Tricyclo-phosphorothioate dna

Publications (1)

Publication NumberPublication Date
IN2014DN03463Atrue IN2014DN03463A (en)2015-06-05

Family

ID=44799824

Family Applications (1)

Application NumberTitlePriority DateFiling Date
IN3463DEN2014IN2014DN03463A (en)2011-10-132014-04-30

Country Status (14)

CountryLink
US (1)US9738891B2 (en)
EP (2)EP2581448B1 (en)
JP (1)JP6181653B2 (en)
CN (1)CN104245935B (en)
AU (1)AU2012322903B2 (en)
BR (1)BR112014009066B8 (en)
CA (2)CA2776651C (en)
DK (1)DK2581448T3 (en)
ES (2)ES2535654T3 (en)
IL (1)IL231983B (en)
IN (1)IN2014DN03463A (en)
PL (1)PL2581448T3 (en)
PT (1)PT2581448E (en)
WO (1)WO2013053928A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ATE498685T1 (en)2004-06-282011-03-15Univ Western Australia ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHOD FOR THE USE THEREOF
CA2596506C (en)2005-02-092021-04-06Avi Biopharma, Inc.Antisense composition and method for treating muscle atrophy
CN105779453A (en)2008-10-242016-07-20萨雷普塔治疗公司Multiple exon skipping compositions for DMD
KR102113306B1 (en)2009-11-122020-05-21더 유니버시티 오브 웨스턴 오스트레일리아Antisense Molecules and Methods for Treating Pathologies
US20130085139A1 (en)2011-10-042013-04-04Royal Holloway And Bedford New CollegeOligomers
KR102390965B1 (en)2013-03-142022-04-26사렙타 쎄러퓨틱스 인코퍼레이티드Exon skipping compositions for treating muscular dystrophy
CN113633787A (en)2013-03-152021-11-12萨勒普塔医疗公司Improved composition for treating muscular dystrophy
IL300444A (en)2013-09-052023-04-01Sarepta Therapeutics IncAntisense-induced exon2 inclusion in acid alpha-glucosidase
EP3480312A1 (en)2013-09-112019-05-08Synthena AGNucleic acids and methods for the treatment of pompe disease
JP6872479B2 (en)2014-07-312021-05-19アソシアシオン・アンスティテュ・ドゥ・ミオロジーＡｓｓｏｃｉａｔｉｏｎ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｍｙｏｌｏｇｉｅ Treatment of amyotrophic lateral sclerosis
BR112017004056A2 (en)2014-09-122017-12-05Biogen Ma Inc compositions and methods for detecting smn protein in an individual and treating an individual
MA41795A (en)2015-03-182018-01-23Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
MA50829A (en)2015-06-012018-04-11Sarepta Therapeutics Inc EXCLUSION OF EXON INDUCED BY ANTISEN TECHNOLOGY IN TYPE VII COLLAGEN
EP3353301A1 (en)2015-09-212018-08-01Association Institut de MyologieAntisense oligonucleotides and uses thereof
EA201890908A1 (en)2015-10-092018-10-31Сарепта Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY OF YOUNG AND SIMILAR DISORDERS
WO2017136435A1 (en)2016-02-012017-08-10The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of HealthCompounds for modulating fc-epsilon-ri-beta expression and uses thereof
JP7033547B2 (en)2016-04-182022-03-10サレプタ セラピューティクス， インコーポレイテッド Antisense oligomers for treating diseases associated with the acidic alpha-glucosidase gene and methods using them
NZ747685A (en)2016-04-292023-05-26Sarepta Therapeutics IncOligonucleotide analogues targeting human lmna
SG11201809497RA (en)2016-05-242018-12-28Sarepta Therapeutics IncProcesses for preparing phosphorodiamidate morpholino oligomers
MX384727B (en)2016-05-242025-03-14Sarepta Therapeutics Inc PROCESSES FOR PREPARING OLIGOMERS
MA45362A (en)2016-05-242019-04-10Sarepta Therapeutics Inc PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE
PT3464306T (en)2016-05-242024-05-17Sarepta Therapeutics IncProcesses for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en)2016-05-242022-10-18Sarepta Therapeutics, Inc.Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810143PA (en)2016-06-302019-01-30Sarepta Therapeutics IncExon skipping oligomers for muscular dystrophy
WO2018055577A1 (en)2016-09-232018-03-29Synthena AgMixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
EP3516061A1 (en)2016-09-232019-07-31Synthena AGMixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
KR102552428B1 (en)2016-12-192023-07-06사렙타 쎄러퓨틱스 인코퍼레이티드 Exon skipping oligomeric conjugates for dyskinesia
RS63705B1 (en)2016-12-192022-11-30Sarepta Therapeutics Inc OLIGOMER CONJUGATES FOR EXON SKIPPING FOR MUSCULAR DYSTROPHY
MX2019006879A (en)2016-12-192019-08-01Sarepta Therapeutics Inc EXON OMISSION OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY.
EP3612215B1 (en)2017-04-202024-08-28aTyr Pharma, Inc.Compositions for treating lung inflammation
WO2018193428A1 (en)2017-04-202018-10-25Synthena AgModified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
KR20250038815A (en)*2017-04-202025-03-19신테나 아게Modified Oligomeric Compounds Comprising Tricyclo-DNA Nucleosides And Uses Thereof
EA201991450A1 (en)2017-09-222019-12-30Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
EP3687577A1 (en)2017-09-282020-08-05Sarepta Therapeutics, Inc.Combination therapies for treating muscular dystrophy
US20200248178A1 (en)2017-09-282020-08-06Sarepta Therapeutics, Inc.Combination therapies for treating muscular dystrophy
US20200254002A1 (en)2017-09-282020-08-13Sarepta Therapeutics, Inc.Combination therapies for treating muscular dystrophy
WO2019079637A2 (en)2017-10-182019-04-25Sarepta Therapeutics, Inc.Antisense oligomer compounds
US10758629B2 (en)2018-05-292020-09-01Sarepta Therapeutics, Inc.Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en)2018-06-132022-06-22Sarepta Therapeutics, Inc. EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
TW202449155A (en)2018-07-272024-12-16美商薩羅塔治療公司Exon skipping oligomers for muscular dystrophy
EP3894558A1 (en)2018-12-132021-10-20Sarepta Therapeutics, Inc.Exon skipping oligomer conjugates for muscular dystrophy
EP3955966A1 (en)2019-04-182022-02-23Sarepta Therapeutics, Inc.Compositions for treating muscular dystrophy
BR112022008856A2 (en)2019-11-062022-08-23Association Inst De Myologie COMBINED THERAPY FOR MUSCULAR DISEASES
TW202517787A (en)2020-02-282025-05-01美商Ionis製藥公司Compounds and methods for modulating smn2
BR112022020412A2 (en)2020-04-092023-05-02Association Inst De Myologie ANTI-SENSE SEQUENCES TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
EP3978608A1 (en)2020-10-052022-04-06SQY TherapeuticsOligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
CA3233242A1 (en)2021-09-302023-04-06Sarepta Therapeutics, Inc.Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en)2021-10-222023-04-27Sarepta Therapeutics, Inc.Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2024064237A2 (en)2022-09-212024-03-28Sarepta Therapeutics, Inc.Dmd antisense oligonucleotide-mediated exon skipping efficiency
US20250066776A1 (en)2023-04-272025-02-27Sarepta Therapeutics, Inc.Antisense oligomers for treatment of chronic kidney disease
WO2025085810A2 (en)2023-10-182025-04-24Sarepta Therapeutics, Inc.Antisense oligomers for treatment of centronuclear myopathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5820873A (en)1994-09-301998-10-13The University Of British ColumbiaPolyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en)1994-09-301998-05-19Inex Pharmaceuticals CorporationCompositions for the introduction of polyanionic materials into cells
US5885613A (en)1994-09-301999-03-23The University Of British ColumbiaBilayer stabilizing components and their use in forming programmable fusogenic liposomes
WO1999031262A2 (en)1997-12-161999-06-24Valentis, Inc.Needle-free injection of formulated nucleic acid molecules
JP2002537828A (en)1999-03-102002-11-12フォゲン リミティド Delivery of substances to cells
CA2520550A1 (en)*2003-04-132004-10-28Enzon Pharmaceuticals, Inc.Polymeric oligonucleotide prodrugs
WO2007073149A1 (en)*2005-12-222007-06-28Keygene N.V.Alternative nucleotides for improved targeted nucleotide exchange
KR20090055623A (en)*2006-09-152009-06-02엔존 파마슈티컬즈, 인코포레이티드 Hindered Ester-Based Biodegradable Linkers for Oligonucleotide Delivery
ES2694726T3 (en)*2007-06-292018-12-26Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en)*2007-06-292010-01-21Avi Biopharma, Inc.Compound and method for treating myotonic dystrophy
CN102231950A (en)*2008-11-172011-11-02安龙制药公司Releasable polymeric lipids for nucleic acids delivery systems
PT2417257E (en)*2009-04-102016-06-03Universität BernTricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
US20140022812A1 (en)2011-02-252014-01-23Lumitex, Inc.Display front lighting device

Also Published As

Publication numberPublication date
BR112014009066B1 (en)2020-08-25
IL231983B (en)2018-04-30
EP2581448A1 (en)2013-04-17
DK2581448T3 (en)2015-04-27
CN104245935A (en)2014-12-24
ES2535654T3 (en)2015-05-13
CA2851970A1 (en)2013-04-18
EP2766479B1 (en)2017-09-13
EP2581448B1 (en)2015-01-28
CA2776651A1 (en)2013-04-13
CA2776651C (en)2021-06-08
US20140296323A1 (en)2014-10-02
US9738891B2 (en)2017-08-22
ES2651216T3 (en)2018-01-25
BR112014009066A2 (en)2017-04-18
WO2013053928A1 (en)2013-04-18
BR112014009066B8 (en)2021-02-23
HK1186205A1 (en)2014-03-07
EP2766479A1 (en)2014-08-20
AU2012322903B2 (en)2017-09-14
AU2012322903A1 (en)2014-05-29
BR112014009066A8 (en)2018-01-09
JP2015501144A (en)2015-01-15
PL2581448T3 (en)2015-08-31
CN104245935B (en)2018-05-08
JP6181653B2 (en)2017-08-16
PT2581448E (en)2015-05-21
IL231983A0 (en)2014-05-28

Similar Documents

PublicationPublication DateTitle
IN2014DN03463A (en)
EP2794630A4 (en)Substituted phosphorothioate nucleotide analogs
IL272953B (en)Substituted nucleosides, nucleotides and analogs thereof
MX2014003979A (en)Modified nucleosides, nucleotides, and nucleic acids, and uses thereof.
HK1200484A1 (en) Polyoligonucleotide compound
EP2799548A4 (en) ANTISENSE NUCLEIC
SI2612917T1 (en)Antisense nucleic acid
IL232558A0 (en)Protein purification using bis-tris buffer
MX353621B (en)Alpha-amylase variants.
EP2776574B8 (en)Methods for determining nucleotide sequence repeats
GB201118636D0 (en)Nucleotide sequence
GB2503856B (en)Methods for nucleic acid purification
ZA201308477B (en)Immunostimulatory oligodeoxynucleotides
ZA201308479B (en)Immunostimulatory oligodeoxynucleotides
ZA201402046B (en)Nucleic acid enzyme substrates
BR112013020427A8 (en) small interference channels with target-specific seed sequences
ZA201400484B (en)Nucleic acid molecules encoding enzymes that confer disease resistance injute
EP2770054A4 (en) ACTIVATION OF FUNCTIONAL NUCLEIC ACID BY SPECIFIC MODIFICATION
GB201117880D0 (en)Antisense oligonucleotides
GB201121713D0 (en)Novel clip
AU2011900015A0 (en)Novel Antisense Oligonucleotides
AU2011900497A0 (en)Clip peg
GB201105387D0 (en)Nucleic acid probes
GB201107940D0 (en)Methods, compositions, and kits for determining variant nucleic acid sequence
EP2782925C0 (en)Protein purification using bis-tris buffer
[8]ページ先頭
©2009-2025 Movatter.jp